Key facts
- Veralox Therapeutics’s last known valuation is $66.0M (Jun 2023).
- It has raised $41.2M across 3 recorded rounds; the latest was Early Stage VC ($24.0M) in Jun 2023.
- Notable investors include Alumni Ventures, Alexandria Venture Investments, TEDCO, NYBC Ventures, Point Field Partners — 15 tracked in total.
- Veralox Therapeutics has filed 3 Form Ds with the SEC since 2019, most recently Jun 2023 ($24.0M sold to 14 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Veralox Therapeutics
Funding rounds
3 roundsAbout Veralox Therapeutics
Developer of small molecule therapeutics designed to target heparin-induced thrombocytopenia and thrombosis. The company's therapeutics focus on new treatment paradigms and improved outcomes for patients based on the understanding of the molecular mechanisms of diabetes diseases, enabling patients to achieve complete recovery from diabetes.
- Sector
- Healthcare
- HQ
- Frederick, MD, United States
- Founded
- 2017
- Employees
- 18
- Website
- veralox.com/
- Ownership
- Privately Held (backing)
Veralox Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Veralox Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Veralox Therapeutics in its N-PORT filings yet. We sweep new filings monthly.